Globus Medical INC 8-K filings

Globus Medical, Inc. announced that its stockholders approved an amendment to the 2021 Equity Incentive Plan, increasing authorized shares and re-electing directors.

Globus Medical announced robust first quarter 2026 financial results, with worldwide net sales up 27.0% and non-GAAP diluted EPS increasing 64.7%.

Globus Medical announced the immediate resignation of Dr. John A. DeFord from its Board of Directors, effective March 23, 2026.

Globus Medical reported robust fourth-quarter and full-year 2025 financial results, driven by strong sales growth and successful integration of acquisitions, leading to an upward revision of its 2026 non-GAAP EPS guidance.

Globus Medical announced preliminary record fourth quarter and full year 2025 sales, along with robust 2026 financial guidance.

Globus Medical, Inc. reported strong third-quarter 2025 financial results, with worldwide net sales increasing 22.9% to $769.0 million and a significant increase in full-year 2025 guidance.

Globus Medical reported strong second-quarter 2025 financial results, with worldwide net sales increasing 18.4% and GAAP net income surging over 500% primarily due to a bargain purchase gain and tax benefit.

Globus Medical, Inc. announced a leadership transition with Keith Pfeil appointed as the new President and CEO, alongside preliminary second-quarter 2025 sales of approximately $745.3 million, an 18.4% increase year-over-year.

Globus Medical, Inc. announced that its stockholders approved an amendment to the 2021 Equity Incentive Plan, re-elected four directors, ratified its independent auditor, and approved executive compensation at its 2025 Annual Meeting.

Globus Medical's Board of Directors has authorized a $500 million share repurchase program, signaling confidence in the company's long-term value despite recent market volatility.

Globus Medical's worldwide net sales decreased by 1.4% in the first quarter of 2025, but the company reaffirms its full-year revenue guidance and expresses confidence in future growth.

Globus Medical successfully completed its acquisition of Nevro Corp on April 3, 2025, marking a significant expansion into the neuromodulation space.

Globus Medical announces a 60.6% increase in worldwide net sales for the full year 2024, driven by the NuVasive merger and strong performance in spine products and enabling technology.

Globus Medical will acquire Nevro Corp. for $5.85 per share in an all-cash transaction valued at approximately $250 million, aiming to expand treatment options for patients and enhance market penetration.

Globus Medical reported record preliminary sales for the fourth quarter and full year 2024, driven by the NuVasive merger, and provided revenue and earnings guidance for 2025.

Globus Medical announced a significant 63.1% increase in worldwide net sales for the third quarter of 2024, alongside strong earnings growth and an increased full-year revenue guidance.

Globus Medical received a warning letter from the FDA citing deficiencies in their response to previous observations regarding complaint procedures for the ExcelsiusGPS robotic system.

Globus Medical announced a significant increase in sales and adjusted EBITDA for the second quarter of 2024, primarily driven by the acquisition of NuVasive.

Globus Medical's stockholders approved an amendment to the 2021 Equity Incentive Plan at the 2024 Annual Meeting, along with the election of directors and other proposals.

Globus Medical announced a significant increase in first quarter 2024 sales, driven by the NuVasive merger, with worldwide net sales up 119.3% year-over-year.

Globus Medical's fourth quarter and full year 2023 results show significant revenue growth driven by the NuVasive merger, with record sales and increased earnings.

Globus Medical has promoted Keith Pfeil to the dual role of Chief Operating Officer and Chief Financial Officer, effective February 1, 2024.